Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven clinical-stage drug discovery company, today announced the nomination of ISM6331, a potential best-in-class pan-TEAD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback